SEC Comment Letter for ALTERITY THERAPEUTICS LTD (ATHE, PRNAF) (CIK 0001131343) (ATHE) — Nov 18, 2020

ALTERITY THERAPEUTICS LTD (ATHE, PRNAF) (CIK 0001131343)
Date: Nov. 18, 2020 · CIK: 0001131343 · Accession: 0000000000-20-011056

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-250076

Date

November 18, 2020

Author

Not clearly detected

Form

UPLOAD

Company

ALTERITY THERAPEUTICS LTD (ATHE, PRNAF) (CIK 0001131343)

Letter

United States securities and exchange commission logo November 18, 2020 Geoffrey Kempler Chief Executive Officer Alterity Therapeutics Limited ABN 37 080 699 065 Level 3, 460 Bourke Street Melbourne, Victoria 3000 Australia Re:Alterity Therapeutics Limited Registration Statement on Form F-3 Filed November 13, 2020 File No. 333-250076 Dear Mr. Kempler: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Deanna Virginio at 202-551-4530 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven J. Glusband, Esq.

Show Raw Text

United States securities and exchange commission logo
November 18, 2020
Geoffrey Kempler
Chief Executive Officer
Alterity Therapeutics Limited
ABN 37 080 699 065
Level 3, 460 Bourke Street
Melbourne, Victoria 3000 Australia
Re:Alterity Therapeutics Limited
Registration Statement on Form F-3
Filed November 13, 2020
File No. 333-250076
Dear Mr. Kempler:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Deanna Virginio at 202-551-4530 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Steven J. Glusband, Esq.

SecProbe.io